CClinicalTrials.gg
Not yet recruitingNCT07276230ENTRAIDANTUpdated Dec 29, 2025

Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma

An interventional study of Therapeutic Education and Needs Assessment Program for Caregivers in Caregivers of Patients With Multiple Myeloma, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The diagnosis and treatment of multiple myeloma affect not only the patient but also their family and caregivers. Advances in therapy have transformed the follow-up of patients treated for multiple myeloma. The involvement of informal caregivers has become increasingly essential to ensure adequate home-based care, as most treatments are now delivered on an outpatient basis. Literature reviews suggest that caregivers of cancer patients often face unmet supportive care needs, which in turn negatively impact their quality of life.

Read the detailed description

By improving the quality of life of caregivers, the intervention can help prevent cascading effects such as a deterioration in the quality of life of the care recipient, thereby reducing the overall burden on healthcare systems. In addition, therapeutic education is an ongoing process aimed at helping patients and/or caregivers acquire or maintain the skills they need to best manage their lives with a chronic condition.

Study procedures :

  1. During the hematology consultation, the study will be presented to the caregiver identified by the patient (between Day -7 and Day 0). After receiving full oral and written information, the caregiver's free, written, and informed consent will be obtained prior to participation.
  2. After providing written informed consent to participate in the study, the caregiver will attend an individual interview at Day 0 with a nurse to complete a Shared Educational Assessment .The caregiver will then independently complete a self-administered questionnaire assessing quality of life using the CarGOQoL (CareGiver Oncology Quality of Life).

    The Shared Educational Assessment is a discussion between the healthcare professional and the caregiver focusing on the skills to be acquired or strengthened in order to improve health and quality of life. It enables exploration and assessment of the caregiver's needs and resources in terms of :

    • Acquisition of knowledge;
    • Acquisition or reinforcement of self-care and coping skills, while recognizing and valuing the caregiver's own self learning efforts.
  3. The group of caregivers thus constituted will attend four therapeutic education workshops. Each workshop will last approximately 1 hour and 30 minutes. Caregivers will attend two half-day sessions, participating in two workshops per session (Week 1: Workshops 1 \& 2; Week 2: Workshops 3 \& 4).

    The topics addressed in the workshops are as follows:

    • Workshop 1: Understanding the disease
    • Workshop 2: Identifying abnormalities in biological tests and adapting the appropriate response
    • Workshop 3: Understanding treatments and their adverse effects
    • Workshop 4: Expressing personal experiences and feelings caregivers' satisfaction with each workshop will be assessed at the end of every session
  4. At the end of the program (three months after inclusion), the caregiver will attend a follow-up consultation with the nurse to evaluate skill acquisition and will independently complete the same quality of life questionnaire (CarGOQoL) that was administered prior to the program
  5. At six months, a new assessment of quality of life will be conducted using the CarGOQoL questionnaire during a telephone interview with a member of the investigative team

The questionnaire will be available in paper format, and the responses will be entered into an electronic case report form (e-CRF) using the CleanWeb system. The data will be analyzed by the Clinical Research Unit (URC).

02

Conditions studied

  • Caregivers of Patients With Multiple Myeloma

Browse trials for

Keywords

  • caregivers
  • multiple myeloma
03

In context

Multiple Myeloma

3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.

This study's planned enrollment of 27 is below the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Caregiver :

  • Designated by a patient followed for multiple myeloma during first-line treatment
  • Providing weekly assistance to the patient (e.g., shopping, housekeeping, management of daily living activities, healthcare or hygiene support, etc.)
  • Aged 18 years or older
  • Fluent in French
  • Affiliated with or benefiting from a social security system (excluding state medical aid - AME)
  • Able to provide free, written, and informed consent

Exclusion criteria

Exclusion Criteria:

Caregiver :

  • Not designated by the patient as the primary caregiver
  • Currently being treated for an acute medical condition
  • Refusal of the caregiver to participate in the study
  • Under legal protection (guardianship or curatorship)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Caregivers

    Therapeutic Education and Needs Assessment Program for Caregivers of Patients with Multiple Myeloma

    Other: Therapeutic Education and Needs Assessment Program for Caregivers

Interventions

  • OtherTherapeutic Education and Needs Assessment Program for Caregivers

    Participation in a weekly therapeutic education group for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Effectiveness of a needs assessment approach through participation in a therapeutic education program on improving the quality of life of caregivers of patients with multiple myeloma.

    Change in caregivers' CarGOQoL (CareGiver Oncology Quality of Life) scores between baseline and 3 months. The higher the score, the better the quality of life.

    Time frame: 3 months

Secondary outcomes

  1. Caregivers' adherence to the therapeutic education program for caregivers of patients with multiple myeloma

    Proportion of caregivers who completed the entire therapeutic education program

    Time frame: 3 months

  2. Changes in caregivers' specific skills after participation in the program (self-care and coping skills)

    Assessment of self-care and coping skills using a four-level competency acquisition scale: acquired, not acquired, introduced, and reinforcement session required

    Time frame: 6 months

  3. Caregivers' satisfaction with participation in the workshops

    Caregivers' satisfaction measured using a Visual Analogue Scale (VAS) ranging from 1 to 10. The higher the score, the greater the satisfaction.

    Time frame: 2 weeks

  4. The long-term effectiveness of this approach on caregivers' quality of life.

    Change in caregivers' CarGOQoL (CareGiver Oncology Quality of Life) scores between baseline and 6 months. The higher the score, the better the quality of life.

    Time frame: 6 months

07

Study locations

1 site
  • Hématologie clinique - Pitié-Salpêtrière Hospital (APHP)
    Paris, 75013, France
08

References and documents

Individual participant data

Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07276230
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Feb 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Anne LE BORGNE, Mrs
Contact
anne.le-borgne@aphp.fr
01 84 82 83 15 ext. + 33
Laurent Dr GARDERET, MD
Contact
laurent.garderet@aphp.fr
01 42 16 27 94 ext. + 33
Anne LE BORGNE, Mrs
principal investigator · Hospital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion